 Zacks Investment Research upgraded shares of Aclaris Therapeutics NASDAQ:ACRS from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. The brokerage currently has 1.25 price objective on the biotechnology companys stock. According to Zacks, Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, ... 